ApprovalTrail

Approval · Notice of Compliance 4645 · 1996

RISPERDAL: Notice of Compliance 4645

Issued February 14, 1996

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
4645
Date
February 14, 1996
Company
Janssen PharmaceuticaBeerse, Saone Et Loire, Belgium
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Provides for revised product monograph
Therapeutic class
Antipsychotic agent

Products in this notice

BrandDINStatus today
RISPERDALNot yet assigned—

Medicinal ingredients